ABSTRACT
Pouteria caimito (Sapotaceae) is widely distributed throughout Latin America, including Brazil. The yellow fruits, known as abiu, caimito, or abiurana, are eaten in natura or used to prepare desserts. In addition to being a commercially available Brazilian fruit, P. caimito has also been used as a traditional medicine. Therefore, hexane, ethanol, and aqueous extracts from its leaves were evaluated for radical-scavenging activity. Free radical-scavenging activity was tested using the DPPH assay. Total phenolic and proanthocyanidin contents were also determined. The aqueous extract comprised the highest total phenol and proanthocyanidin contents (173.6 g/mL) and showed the highest radical-scavenging activity (ED50= 36.1 g/mL). Phytochemical analysis of the hexane extract allowed the isolation of spinasterol. We found a high correlation between total phenolic and proanthocyanidin contents and radical-scavenging activity. To our knowledge, this is the first time spinasterol has been isolated from P. caimito leaves.
ABSTRACT
The National Policy of Integrative and Complementary Practices (PNPIC) in the Brazilian Unified Health System (SUS), and The National Policy of Medicinal Plants and Herbal Medicines (PNPMF) were launched in 2006. Based on these, the Brazilian Health Surveillance Agency (ANVISA) re-edited rules related to herbal medicines such as the Guideline to herbal medicine registration (RDC 14/10), the Good Manufacture Practices Guideline (RDC 17/10) and the List of references to assess the safety and efficacy of herbal medicines (IN 05/10). The requisites to prove herbal medicine's safety and efficacy were updated. Therefore, this review aims at presenting and commenting these new rules.
Em 2006, dois importantes documentos foram publicados no Brasil: a Política Nacional de Práticas Integrativas e Complementares (PNPIC) no Sistema Único de Saúde (SUS) e a Política Nacional de Plantas Medicinais e Fitoterápicos (PNPMF) à luz das quais a ANVISA avaliou as normas para o setor. Como produto dessa avaliação, foram republicadas as normas para registro de medicamentos fitoterápicos, por meio da Resolução de Diretoria Colegiada (RDC) 14/10, as Boas Práticas de Fabricação e Controle de medicamentos na indústria farmacêutica, RDC 17/10, e a lista de referências para comprovação da segurança e eficácia de medicamentos fitoterápicos, na forma da Instrução Normativa (IN) 05/10. Em relação às normas anteriormente vigentes, foram atualizados os requisitos para comprovação da segurança e eficácia destes medicamentos e sugeridas alternativas ao controle da qualidade de cada etapa de produção. Dessa forma, essa revisão tem por objetivo apresentar tais normas destacando suas características principais.